Baseline characteristics of participants without a history of prior SARS-CoV-2 infection, who received uninterrupted biological therapy since recruitment and had an antibody test between 14 and 70 days after a third dose with an mRNA-based SARS-CoV-2 vaccine
| Variable | Level | Vedolizumab | Infliximab | Overall | P value |
| Vaccine | BNT162b2 | 41.9% (185/442) | 41.5% (381/918) | 41.6% (566/1360) | 0.91 |
| ChAdOx1 nCoV-19 | 58.1% (257/442) | 58.5% (537/918) | 58.4% (794/1360) | ||
| Age (years) | 51.7 (37.9–63.4) | 43.7 (32.3–55.6) | 46.3 (33.6–58.3) | <0.0001 | |
| Sex | Female | 50.6% (223/441) | 46.4% (424/914) | 47.7% (647/1355) | 0.12 |
| Male | 49.2% (217/441) | 53.4% (488/914) | 52.1% (706/1355) | ||
| Intersex | N<5 | N<5 | N<5 | ||
| Prefer not to say | N<5 | N<5 | N<5 | ||
| Ethnicity | White | 93.0% (410/441) | 95.2% (870/914) | 94.5% (1280/1355) | 0.32 |
| Asian | 5.0% (22/441) | 2.7% (25/914) | 3.5% (47/1355) | ||
| Mixed | 1.1% (5/441) | 1.1% (10/914) | 1.1% (15/1355) | ||
| Black | N<5 | 0.5% (5/914) | 0.5% (7/1355) | ||
| Other | N<5 | 0.4% (4/914) | 0.4% (6/1355) | ||
| Diagnosis | Crohn’s disease | 36.7% (162/442) | 70.2% (644/918) | 59.3% (806/1360) | <0.0001 |
| UC/IBDU | 63.3% (280/442) | 29.8% (274/918) | 40.7% (554/1360) | ||
| Duration of IBD (years) | 10.0 (5.0–19.0) | 9.0 (4.0–17.0) | 9.0 (4.0–18.0) | 0.0064 | |
| Age at IBD diagnosis (years) | 36.0 (22.7–48.5) | 29.8 (21.4–41.6) | 31.2 (21.9–44.1) | <0.0001 | |
| Immunomodulators at vaccine | 19.9% (88/442) | 58.7% (539/918) | 46.1% (627/1360) | <0.0001 | |
| 5-ASA | 33.9% (150/442) | 21.6% (198/918) | 25.6% (348/1360) | <0.0001 | |
| Steroids | 5.7% (25/442) | 2.4% (22/918) | 3.5% (47/1360) | 0.0038 | |
| BMI | 25.8 (23.1–29.7) | 26.1 (22.9–30.4) | 25.9 (23.0–30.3) | 0.88 | |
| Heart disease | 7.3% (32/440) | 2.9% (26/912) | 4.3% (58/1352) | 0.00029 | |
| Diabetes | 8.2% (36/440) | 4.5% (41/912) | 5.7% (77/1352) | 0.0082 | |
| Lung disease | 16.1% (71/440) | 12.0% (109/912) | 13.3% (180/1352) | 0.040 | |
| Kidney disease | 2.3% (10/440) | 1.2% (11/912) | 1.6% (21/1352) | 0.16 | |
| Cancer | 1.1% (5/440) | N<5 | 0.5% (7/1352) | 0.040 | |
| Smoker | Yes | 6.1% (27/440) | 8.4% (77/912) | 7.7% (104/1352) | 0.17 |
| Not currently | 37.5% (165/440) | 33.3% (304/912) | 34.7% (469/1352) | ||
| Never | 56.4% (248/440) | 58.2% (531/912) | 57.6% (779/1352) | ||
| Exposure to documented cases of COVID-19 | 7.0% (31/440) | 7.5% (68/912) | 7.3% (99/1352) | 0.82 | |
| Income deprivation score | 0.090 (0.054–0.140) | 0.087 (0.053–0.142) | 0.088 (0.053–0.141) | 0.83 | |
| Active disease (PRO2) | 20.4% (85/416) | 23.5% (203/864) | 22.5% (288/1280) | 0.23 | |
| Time between first two vaccine doses (weeks) | 10.9 (10.0–11.1) | 11.0 (10.0–11.1) | 11.0 (10.0–11.1) | 0.51 | |
| Time between second and third vaccine doses (weeks) | 27.3 (25.6–28.9) | 26.8 (24.3–28.4) | 27.0 (24.7–28.7) | 0.00064 | |
| Time from second dose to serum sample (weeks) | 32.8 (30.4–35.4) | 32.1 (29.6–35.1) | 32.4 (29.9–35.1) | 0.016 | |
| Time from third dose to serum sample (weeks) | 5.6 (3.9–7.7) | 5.7 (3.7–7.6) | 5.7 (3.8–7.6) | 0.93 | |
Values presented are median (IQR) or percentage (numerator/denominator). P values represent the results of a Mann-Whitney U test, Kruskal-Wallis test or Fisher’s exact test.
5-ASA, 5-aminosalicylic acid; BMI, body mass index; IBDU, IBD unclassified; mRNA, messenger RNA; PRO2, IBD disease activity.